Ochsner MD Anderson Cancer Center has achieved a sweeping set of national validations that underscore its role as a hub of sophisticated oncology care in Louisiana. Eight of its locations have earned accreditation from the American College of Surgeons Commission on Cancer, two breast centers have been re-accredited under the National Accreditation Program for Breast Centers, and the Gayle and Tom Benson Cancer Center has become the state’s first sarcoma treatment center listed by the Sarcoma Foundation of America and the Sarcoma Alliance for Research through Collaboration. These milestones, announced together, signal a deliberate alignment with the most exacting standards in multidisciplinary cancer management.
The Commission on Cancer (CoC) accreditation, renewed every three years, is not a passive certificate. It demands that a program demonstrate compliance with more than 30 standards spanning program management, clinical services, continuum of care, and quality improvement. For a cancer center, this means maintaining a registry of all cancer cases for lifetime follow-up, conducting regular cancer conferences where surgeons, medical oncologists, radiation oncologists, pathologists, and radiologists collectively chart treatment pathways, and implementing evidence-based guidelines that govern everything from surgical resection margins to psychosocial distress screening. When eight geographically dispersed Ochsner sites simultaneously satisfy these requirements, it indicates a system-wide infrastructure for consistent, protocol-driven care—rare outside large academic networks.
Equally significant is the NAPBC accreditation for the Lieselotte Tansey Breast Cancer Center and the St. Tammany Cancer Center campus. NAPBC standards specifically target the patient journey through breast disease, demanding not only clinical excellence in imaging, biopsy, and surgery but also seamless navigation, genetic counseling, and survivorship planning. A center must prove that digital breast tomosynthesis is available and utilized, that needle biopsies are performed percutaneously rather than via open surgery for initial diagnosis in at least 90% of cases, and that multidisciplinary review occurs before treatment initiation. The re-accreditation confirms that these metrics have been met consistently across multiple cycles.
The recognition by the Sarcoma Alliance for Research through Collaboration and the Sarcoma Foundation of America fills a critical regional gap. Soft tissue sarcomas and bone sarcomas are rare, heterogeneous malignancies that demand a specific convergence of expertise: orthopedic oncology, dedicated sarcoma pathologists who can interpret molecular markers like MDM2 and SS18-SSX fusions, and interventional radiologists skilled in complex biopsies that do not compromise future resection planes. Ochsner’s listing as a sarcoma center indicates it has a formalized tumor board for sarcomas, access to clinical trials through collaborative groups, and a coordinated approach to limb-salvage surgery and adjuvant therapies. For patients in Louisiana, this eliminates the need to travel to distant NCI-designated centers for standard-of-care sarcoma management.
The announcement also brings the designation of ACS Surgical Quality Partner, a marker that extends beyond oncology. This status is conferred on institutions that participate in ACS quality programs such as the National Surgical Quality Improvement Program (NSQIP). Participation requires robust data collection on 30-day surgical outcomes, including risk-adjusted morbidity and mortality, with ongoing internal audits. For a cancer center, this means that the same quality lens applied to a colectomy or mastectomy is also scrutinizing the outcomes of a complex sarcoma resection or a cytoreductive surgery. Patients can thus expect that the safety infrastructure is pervasive, regardless of the specific procedure.
Zoe Larned, MD, director of Ochsner MD Anderson Cancer Center, framed the recognitions as a testament to patient-centered, community-embedded innovation. Her emphasis on care “close to home” is not trivial. Travel distance to an accredited cancer program is an independent predictor of clinical trial participation and adherence to guideline-concordant therapy, studies have shown. By saturating the region with accredited sites under a unified MD Anderson partnership, Ochsner may be addressing a persistent health equity gap.
The cancer program’s technical backbone merits attention. It is accredited by the Foundation for the Accreditation of Cellular Therapy, indicating competency in bone marrow transplantation and chimeric antigen receptor T-cell therapies, a highly regulated domain requiring cleanroom facilities and established protocols for cytokine release syndrome management. Integration with MD Anderson brings molecular tumor profiling and an array of clinical trials—more than any other institution in Louisiana, the center claims. Such depth allows for the systematic implementation of precision oncology, where next-generation sequencing results guide therapy selection within a structured protocol rather than ad hoc.
U.S. News & World Report has recognized the system as high-performing in leukemia, lymphoma, myeloma, and surgeries for colon, lung, and prostate cancers. The annual case volume exceeds 40,000 patients, drawn from all 50 states and 28 countries, a geographic reach that suggests the center functions as a tertiary referral hub for complex cases. In an era where cancer care is increasingly fragmented, the convergence of CoC, NAPBC, sarcoma specialization, and Surgical Quality Partner status represents a deliberate counterforce: a codification of integrated, multidisciplinary delivery backed by continuous performance evaluation. The story here is not merely one of plaques and certificates, but of a health system engineering a comprehensive cancer ecosystem that is measured, transparent, and relentlessly benchmarked.
Subject of Research: Accreditation and recognition of multidisciplinary cancer care programs
Article Title: Ochsner MD Anderson Earns Stringent Cancer Accreditations, Becomes Louisiana’s First Listed Sarcoma Center
News Publication Date: 2025
Web References:
– Ochsner Cancer Services: https://www.ochsner.org/services/cancer-care/cancer-services/
– American College of Surgeons Commission on Cancer: https://www.facs.org/quality-programs/cancer-programs/commission-on-cancer/coc-accreditation/
– ACS National Accreditation Program for Breast Centers: https://www.facs.org/quality-programs/cancer-programs/national-accreditation-program-for-breast-centers/
– Sarcoma Foundation of America Treatment Centers: https://curesarcoma.org/support-resources/treatment-centers/
– Sarcoma Alliance for Research through Collaboration: https://sarctrials.org/
– ACS Surgical Quality Partner: https://www.facs.org/quality/
– Ochsner MD Anderson: https://www.ochsner.org/services/cancer-care/cancer-services/
References: None (press release, no external scientific citations)
Image Credits: Not provided
Keywords: cancer accreditation, Commission on Cancer, National Accreditation Program for Breast Centers, sarcoma treatment center, multidisciplinary cancer care, surgical quality, Ochsner MD Anderson, oncology, Louisiana cancer care, health equity, clinical trials
